In patients with chronic obstructive pulmonary disease (COPD), what are the indications for using inhaled corticosteroids and systemic corticosteroids, including criteria such as exacerbation frequency and blood eosinophil count?

Corticosteroid Indications in COPD

For stable COPD patients with moderate to very severe disease, use inhaled corticosteroids (ICS) only in combination with long-acting bronchodilators—specifically when patients have ≥2 exacerbations per year or blood eosinophils ≥300 cells/µL—and reserve systemic corticosteroids exclusively for acute exacerbations, limiting treatment to ≤14 days. 1, 2

Inhaled Corticosteroids (ICS) - Maintenance Therapy

Primary Indications

ICS should NEVER be used as monotherapy in COPD. 1, 3 The evidence-based indications for adding ICS to long-acting bronchodilators are:

1. Exacerbation History (Strongest Indication)

• ≥2 moderate-to-severe exacerbations in the previous year despite optimal bronchodilator therapy 1, 2
• History of hospitalization for COPD exacerbation 2
• This corresponds to GOLD categories C and D 1

2. Blood Eosinophil Count Thresholds

The 2023 Canadian Thoracic Society guideline provides clear cut-offs 2:

• ≥300 cells/µL: Strong indication for ICS addition
• 100-300 cells/µL: ICS may be beneficial, particularly with frequent exacerbations
• <100 cells/µL: Avoid ICS due to increased pneumonia risk without benefit 3, 4

3. Concomitant Asthma

• History of asthma or asthma-COPD overlap is an absolute indication for ICS 3

Combination Therapy Recommendations

The evidence strongly supports specific combinations 1:

• ICS/LABA combination: Recommended over placebo (Grade 1B) or LABA monotherapy (Grade 1C) for preventing exacerbations in moderate-to-very severe COPD 1
• Triple therapy (ICS/LABA/LAMA): Indicated for GOLD category D (very severe COPD with frequent exacerbations) 1, 2
• The ETHOS trial demonstrated 24% reduction in exacerbations with triple therapy versus dual bronchodilators, with a mortality benefit favoring moderate-dose ICS 2

Critical Caveats for ICS Use

Pneumonia risk increases by 38-48% with ICS 1, particularly in:

• Older patients
• Lower BMI
• Higher ICS doses
• Blood eosinophils <100 cells/µL 3

However, the number needed to treat is 4 patients for 1 year to prevent one exacerbation, versus number needed to harm of 33 for one pneumonia case 2. Other common adverse effects include oral candidiasis, dysphonia, and bruising 1.

Do not step down from triple therapy in high-risk patients, especially those with eosinophils ≥300 cells/µL, as ICS withdrawal increases exacerbation risk 2.

Systemic Corticosteroids

Acute Exacerbations (Primary Indication)

For acute COPD exacerbations (outpatient or inpatient), systemic corticosteroids should be given for ≤14 days 1, 5, 6:

• Dosing: 30-40 mg prednisone daily for 5 days (or equivalent) 6
• Route: Oral or intravenous (no difference in efficacy) 1, 5
• Benefit window: Reduces recurrent exacerbations only within the first 30 days post-treatment 1, 5
• Grade of recommendation: 2B for use within 30 days 1, 5

Absolute Contraindications for Long-term Use

Systemic corticosteroids should NOT be used for maintenance therapy beyond 30 days post-exacerbation (Grade 1A) 1, 5. The risks—hyperglycemia, weight gain, infection, osteoporosis, adrenal suppression—far outweigh any benefits for chronic use 1, 5, 1.

Eosinophil-Guided Approach for Exacerbations

Emerging evidence suggests tailoring systemic corticosteroid use during exacerbations based on blood eosinophils 7:

• Patients with eosinophils ≥2% (or ≥0.3 × 10⁹ cells/L) show greater benefit from systemic steroids
• Those with eosinophils <2% may not benefit and could have worse outcomes with steroids 6
• This approach can reduce corticosteroid exposure from 5 days to median 2 days without compromising outcomes 7

Practical Algorithm

For stable COPD:

1. Start with dual bronchodilators (LABA/LAMA)
2. Add ICS if: (a) ≥2 exacerbations/year AND (b) eosinophils ≥300 cells/µL OR history of asthma
3. Consider ICS if: eosinophils 100-300 cells/µL with ongoing exacerbations
4. Avoid ICS if: eosinophils <100 cells/µL (unless asthma history)

For acute exacerbations:

1. Give prednisone 30-40 mg daily × 5 days (or up to 14 days maximum)
2. Consider eosinophil count if available (treat if ≥2%)
3. Never continue systemic steroids beyond 30 days for exacerbation prevention